Form 4: Nexalin Technology's Chief Medical Officer, David Owens, Buys 1,000 Shares
SEC Form 4 Filing
David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,000 shares of common stock at $2.98 per share on February 4, 2025.
Summary
- On February 4, 2025, David Owens, the Chief Medical Officer of Nexalin Technology, Inc., acquired 1,000 shares of the company's common stock.
- The purchase price was $2.98 per share.
- Following this transaction, Owens directly owns 154,793 shares of Nexalin Technology, Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an insider stock purchase, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Stakeholder Impact
- The purchase of shares by a company insider can sometimes be viewed positively by shareholders, as it may indicate confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of transaction: David Owens purchased 1,000 shares of Nexalin Technology, Inc. common stock. |
| 02/04/2025 | Date of signature: David Owens signed the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.